Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) for sarcoma, ewing

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Dec 2018: Trial registered, NCT03778996
  2. 3 Jan 2020: Trial started, NCT03778996

The trials

NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

State
Under way
Phase
Phase 2
People
31 taking part
Started
3 Jan 2020
Primary completion
19 Dec 2027
Arms
Maintenance Treatment: Ewing's Sarcoma, Salvage Treatment: Sarcoma
Results
None posted
  1. 19 Dec 2018: Trial registered
  2. 3 Jan 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.